Image by ThisisEngineering RAEng

JAGUAHR Therapeutics

Targeting the AhR pathway to develop novel immuno-oncology therapeutics

About JAGUAHR Therapeutics

JAGUAHR Therapeutics was established in 2019 as a spin-out from ASLAN Pharmaceuticals, and with initial investment from Bukwang Pharmaceutical, to develop novel immuno-oncology therapeutics targeting the Aryl Hydrocarbon Receptor (AhR) pathway. JAGUAHR Therapeutics is currently in the Discovery phase of its small-molecule AhR antagonist program with a view to delivering clinical candidate drugs.

Image by Dragon Pan

What We Do

JAGUAHR Therapeutics is developing new immuno-oncology therapeutics targeting the AhR pathway.

The Aryl Hydrocarbon Receptor (AhR) is a transcription factor that acts as a key regulator of the immune system. Endogenous ligands of the AhR include metabolic products of tryptophan (TRP) metabolism such as kynurenine, kynurenenic acid and cinnabarinic acid. The rate limiting step in the conversion of tryptophan to kynurenine is catalyzed by the enzymes IDO1, IDO2 or TDO. These are frequently overexpressed in numerous tumor types and convert tryptophan into kynurenine (KYN) which is then secreted into the tumor microenvironment (TME). Elevated IDO and TDO activity and KYN levels are associated with increased tumor grade and poor prognosis in many cancers.

In the TME, KYN and other TRP metabolites, are actively transported into immune cells in which they activate the AhR leading to modulation of the immune system thereby inhibiting immune-mediated clearance of tumor cells. An antagonist of the AhR will reverse this tumor-derived immunomodulation and lead to restoration of immune-mediated killing of cancer cells. An additional advantage of targeting the TRP-KYN-AhR pathway via the AhR is that it is agnostic to whether KYN is produced by IDO1, IDO2 or TDO. Furthermore, the AhR is activated by other immunomodulatory ligands not derived from the TRP-KYN pathway, consequently an antagonist of the AhR may deliver greater efficacy than inhibitors IDO1, IDO2 and TDO. Finally, there is evidence that AhR expressed by tumor cells regulates key processes in tumorigenesis such as proliferation and migration, thus an AhR antagonist may have additional direct beneficial effects on cancer cells.  

In summary, the AhR represents a novel mechanism to treat cancer via a unique combination of immuno-oncology and direct anti-cancer effects.

Jaguahr Graphic-02.tif


The JAGUAHR team

Carl Firth

Chief Executive Officer of ASLAN Pharmaceuticals

Hee-Won Yoo

CEO and President
of Bukwang Pharmaceutical Co., Ltd

Mark Graham

Founder of 448 Therapeutics Limited

Jihye Shin
Senior Manager for Global Business Development of Bukwang Pharmaceutical Co., Ltd.

Rob Moore

Director of R&D
for ASLAN Pharmaceuticals 

Scientific Advisors

John Dixon

Drug Discovery

Martyn Foster

Experimental Pathology

Iain Dougall 


Mike Stocks

Medicinal Chemistry




ASLAN Pharmaceuticals and Bukwang Pharmaceutical establish a Joint Venture, JAGUAHR Therapeutics, to develop novel immuno-oncology therapies

Read more


Relevant Publications

Targeting the IDO1/TDO2-KYN-AhR pathway for cancer immunotherapy — challenges and opportunities

Jae Eun Cheong, Lijun Sun.

Trends Pharmacol. Sci. 39, 307–325 (2018)

Blockade of IDO-kynurenine-AhR metabolic circuitry abrogates IFN-g-induced immunologic dormancy of tumor-repopulating cells

Yuying Liu, Xiaoyu Liang, Xiaonan Yin, Jiadi Lv, Ke Tang, Jingwei Ma, Tiantian Ji, Huafeng Zhang, Wenqian Dong, Xun Jin, Degao Chen, Yanchun Li, Songyan Zhang, Heidi Q. Xie, Bin Zhao, Tong Zhao, Jinzhi Lu, Zhuo-Wei Hu, Xuetao Cao, F. Xiao-Feng Qin, Bo Huang.

Nat. Commun. 8, 15207 (2017)

Cancer immunotherapy by targeting IDO1/TDO and their downstream effectors

Michael Platten, Nikolaus von Knebel Doeberitz, Iris Oezen, Wolfgang Wick, Katharina Ochs.

Front. Immunol. 5, 673 (2015)

Role of the Aryl Hydrocarbon Receptor in Carcinogenesis and Potential as a Drug Target

Stephen Safe, Syng-Ook Lee, Un-Ho Jin.

Toxicological Sciences, 135, (1), 1 – 16 (2013)

The aryl hydrocarbon receptor in tumor immunity

Michael Platten, Ulrike Litzenburger, Wolfgang Wick.

Oncoimmunology, 1, 396–397 (2012)


An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor

Christiane A. Opitz, Ulrike M. Litzenburger, Felix Sahm, Martina Ott, Isabel Tritschler, Saskia Trump, Theresa Schumacher, Leonie Jestaedt, Dieter Schrenk, Michael Weller, Manfred Jugold, Gilles J. Guillemin, Christine L. Miller, Christian Lutz, Bernhard Radlwimmer, Irina Lehmann, Andreas von Deimling, Wolfgang Wick, Michael Platten.

Nature 478, 197 – 203 (2011)